RPG Life Sciences Limited announces an acquisition

The total consideration for the slump sale is Rs 33.55 Crores. The API undertaking is being transferred under a Business Transfer Agreement to RPG Active Pharma Limited, a wholly owned subsidiary, on a slump-sale basis; the reported net worth of the transferred business was Rs 70.92 Crores. ^[1]

Transaction structure

• The transaction is structured as a transfer of the API business as an undertaking rather than as separately priced sales of individual assets. ^[1]
• RPG Active Pharma is the wholly owned subsidiary receiving the business. ^[2]
• The reported consideration of Rs 33.55 Crores is therefore the lump-sum transfer price; it should not be confused with the subsequent Rs 243.33 Crores investment by InvAscent or the broader investment commitment of up to Rs 700 Crores. ^[1]

Asset/liability transfer and tax treatment

The cited disclosure does not reproduce the board-approved valuation report’s detailed schedule specifying:

• which assets are transferred or excluded;
• which liabilities and contingent liabilities are assumed;
• the valuation methodology and allocation used for the undertaking; or
• the precise tax computation, including the relevant tax base, capital-gain treatment, or any tax liability arising to RPG Life Sciences.

Accordingly, the supported conclusion is limited to the Rs 33.55 Crores lump-sum consideration and the slump-sale structure. The exact asset/liability perimeter and tax implications need to be read from the valuation report or the underlying stock-exchange filing, rather than inferred from the news summary.

FY26 API revenue was Rs 95.06 Crores, or 13.54% of company turnover. A separate API EBITDA contribution was not reported in the cited annual/transaction disclosure, so the segment’s EBITDA and EBITDA margin cannot be calculated reliably. ^[1]

Margin impact of the transfer

• Standalone RPG Life Sciences: API revenue and API operating profit will no longer sit in the parent company’s standalone income statement once the business is transferred to RPG Active Pharma. On FY26 numbers, standalone revenue would mechanically reduce from Rs 707.52 Crores by approximately Rs 95.06 Crores, leaving roughly Rs 612.46 Crores before considering transfer-accounting adjustments. The parent’s standalone EBITDA was Rs 172.67 Crores in FY26. ^{[3] [4]}
• Standalone EBITDA margin: The direction of change cannot be quantified without the API EBITDA figure and clarity on which corporate costs are transferred or retained. If API EBITDA margin is below the formulations business, the parent’s standalone margin should rise; if it is higher, standalone margin should decline. This is a mix effect, not necessarily an improvement in underlying group profitability.
• Consolidated RPG Life Sciences: Because RPG Active Pharma is initially a wholly-owned subsidiary, the API business should continue to be consolidated. Therefore, consolidated revenue and EBITDA should retain the API contribution, subject to inter-company eliminations and any one-off transfer costs. The group-level operating margin should be broadly unchanged by the legal restructuring itself; it will change only if the subsidiary has a different cost structure, incurs expansion costs, or grows faster or slower than the formulations business.
• Future ownership: The proposed external investment could ultimately give investors managed by InvAscent approximately 40% of RPG Active Pharma on a fully diluted basis. ^[1] If that occurs, RPG Life Sciences may still consolidate the subsidiary while reporting a minority-interest deduction below EBITDA, affecting consolidated PAT rather than the consolidated EBITDA margin directly.

Analyst read: The transfer will make standalone RPG Life Sciences look more formulations-focused and may alter its standalone margin mechanically. Consolidated margins remain the economically relevant measure for the combined group, but the absence of API EBITDA disclosure prevents a precise standalone-versus-consolidated margin bridge.

RPG Life Sciences’ restructuring is more than a legal reorganisation: it creates a focused API platform with separate capital, management attention and manufacturing expansion. Relative to the peer evidence available, the distinctive feature is the combination of API carve-out, private-equity participation and acquisition-led capacity building, rather than a clearly stated regulatory separation.

RPG Life Sciences

RPG incorporated RPG Active Pharma as a wholly owned subsidiary and transferred the API business to it through a slump sale. The API business generated Rs 95.06 Crores in FY26, or 13.54% of consolidated turnover. InvAscent is to invest up to Rs 243 Crores for a 40% stake, within a broader investment commitment of up to Rs 700 Crores, while RPG Active Pharma has acquired Actis Generics for Rs 80 Crores. ^[5]

Operationally, this creates:

• a dedicated API management and capital-allocation vehicle;
• a two-location manufacturing platform spanning Navi Mumbai and Visakhapatnam; and
• scope for portfolio expansion, process development, organic growth and acquisitions. ^[6]

The structure is therefore initially a WOS, but the proposed 40% InvAscent stake means it is intended to evolve into a parent-controlled subsidiary with an external financial partner, rather than remain a wholly owned captive division.

Peer comparison

Zota Health Care

The cited material does not establish a comparable API subsidiary, WOS structure or separate manufacturing platform for Zota. A direct legal-entity comparison is therefore not possible.

Gufic Biosciences

Gufic’s described operating framework is organised around manufacturing, domestic business, international business and R&D, rather than a disclosed API carve-out. ^[7] A third-party profile lists Gufic’s API and regulatory credentials, including 14 APIs and six USDMFs, but that reflects product or facility-level capability and does not indicate a separate API subsidiary. ^[8]

Morepen Laboratories

Morepen is described as operating across APIs, branded generics or finished dosages, consumer medical devices and home-health products. ^[9] Its API business is presented as a vertically integrated manufacturing operation with USFDA- and WHO-GMP-approved facilities. ^[10] This is closer to an integrated multi-business platform than RPG’s proposed subsidiary-led model.

Unichem Laboratories

The available description frames Unichem primarily through API manufacturing, production, quality control and GMP-compliance activities. ^[11] It does not provide evidence of a separate API WOS or an external-investor-backed carve-out. The comparison is consequently limited to operating orientation rather than corporate structure.

Aarti Drugs

Aarti Drugs is described as a broad manufacturer spanning APIs, intermediates, formulations, specialty chemicals and contract manufacturing. ^[12] Its model appears to retain these activities within a diversified pharma manufacturing platform; the cited material does not show a comparable API WOS transaction.

Does RPG specify a regulatory rationale?

No—not in the disclosed rationale. The stated objectives are to pursue APIs with “greater speed, discipline and scale,” strengthen manufacturing infrastructure, expand the product portfolio and process-development capability, and pursue organic and inorganic growth. ^[6] The announcement does not state that the WOS is being created to establish a distinct regulatory-compliance regime, separate licences, an independent quality system or a different regulatory perimeter.

It does specify a separate manufacturing and business focus. The API business is being housed in a dedicated subsidiary, Actis expands the manufacturing footprint to Visakhapatnam, and the combined platform is expected to operate across Navi Mumbai and Visakhapatnam. ^[5]

Analytical read: the WOS appears primarily designed for strategic focus, external capital mobilisation and API-scale-up execution. Regulatory segregation may be a practical consequence of placing assets and operations in a dedicated entity, but it is not identified as the stated reason for the restructuring.